Abstract

Most patients with minimal change disease (MCD) have a good response to treatment and keep a preserved renal function. Therefore progression to end-stage renal disease (ESRD) is uncommon, seen in less than 5% of patients. This study aimed to Identify the predictor factors of progressing to chronic renal failure (CRF) in adult patients with MCD. This is a retrospective study including adults having NS with biopsy proven MCD from January 2006 to December 2019 in a medical nephrology department. Were compared patients having CRF with those keeping a normal renal function. Statistical analysis included Cox-regression analysis to examine which factors were associated with risk of CRF. 48 adults with biopsy proven MCD were analyzed. 7 (14.58%) patients evolved to CRF. Mean age was higher in patients with CRF, 50.71±23.54 years against 33.21±13.59 years in the other group (p=0,099). They also had higher albumin and protein serum levels, 21.4±5.02 g/l against 16.51±5.01 g/l (p=0.048, r=1.122) and 53.40±6.14g/l against 46.39±7.33g/l (p=0.048, r=1.077). Steroid resistance was also higher in patients with CRF found in 42.9% while no steroid resistance was found among the second group (p=0,003). 50% of patients having focal segmental sclerosis in their second biopsy had evolved to CRF. This study demonstrated that MCD patients who are older and those who have poor response to treatment are more likely to develop CRF. However, low serum albumin and protein levels seem to be protective factors.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.